Glioblastoma (GBM) is the most common malignant primary brain tumor with a low five-year survival rate. Evidence from experimental and clinical studies indicates that glioma stem cells (GSCs) contribute to GBM tumor growth, therapeutic resistance and relapse (Bao et al., 2006; Gilbertson and Rich, 2007). GSCs are enriched in a unique microenvironment known as the perivascular niche. Interestingly, a large number of tumor-associated macrophages (TAMs) are also distributed in the perivascular niche, indicating that crosstalk between GSCs and TAMs may have a critical role in GBM tumor progression. TAMs are abundant in most solid tumors and contribute to tumor progression in several ways, such as promoting invasion, angiogenesis and immunosuppression; however, the molecular link between TAM recruitment and GSCs has remained generally unclear. Writing in *Nature Cell Biology*, Zhou et al. provide new insights into where and how TAMs are recruited and educated by GSCs in GBMs (Zhou et al., 2015) (Fig. 1).

Using *in vitro* migration and invasion assays, Zhou et al. (2015) identified periostin (POSTN) as one of the most abundant GSC-secreted cytokines to potently attract macrophages. TCGA database analyses demonstrated that POSTN expression is negatively related to the survival of GBM patients. The authors further confirmed that POSTN is preferentially expressed and secreted by GSCs in human GBMs. Moreover, TAMs are enriched in POSTN-abundant regions in primary human GBM tissues, indicating that TAM density is positively related to POSTN level in human GBMs. Furthermore, knockdown of POSTN in GSCs significantly inhibits tumor growth and prolongs the survival of mice bearing GSC-derived GBM xenografts. Interestingly, silencing POSTN in GSCs also reduces TAM density by more than 65% in GSC-derived tumors. The authors further demonstrated that conditioned media from non-stem cancer cells do, whereas treatment with an anti-POSTN antibody or knockdown of POSTN in GSCs dramatically attenuates such a chemoattractant effect. PMA-primed U937 cells and TAMs in GBM xenografts and human primary GBM tumors express a POSTN receptor, integrin αvβ3. POSTN can activate Akt in macrophages, and anti-αvβ3 integrin antibody blocks this activation. Remarkably, treating primed U937 cells and GSC-derived GBM xenografts with integrin-inhibitory RGD peptide significantly attenuates POSTN-induced macrophage recruitment and decreases TAM density in GSC-derived GBM xenografts. Thus, POSTN recruits TAMs in GBM tumors via integrin αvβ3 signaling.

TAMs in GBMs are currently thought to be either monocyte-derived macrophages from the peripheral blood or resident brain microglia. To determine the origin of TAMs in GBMs, Zhou et al. (2015) analyzed the specific macrophage markers in GSC-derived xenografts as well as in primary GBM tumors. The authors found that the majority of macrophages are resident microglia (CX3CR1+/CCR2−) in the normal mouse brain, whereas only CCR2+/CX3CR1− macrophages, the monocyte-derived macrophages from the peripheral blood, are found in the GSC-derived GBM xenografts. Moreover, TAMs are CCR2+/CX3CR1− in most human primary GBMs and are abundant around blood vessels both in GSC-derived xenografts and in primary GBM tumors, indicating that the recruited TAMs in GBMs are mainly monocyte-derived macrophages from the peripheral blood. The authors further used M1-specific markers (MHCII and CD11c) and M2-specific markers (Fizz-1, CD163 and Arg1) to determine which TAMs are recruited or maintained by GSC-derived POSTN. Knockdown of POSTN in GSCs markedly reduces M2 TAMs in GBM tumors, whereas overexpression of POSTN in GSCs promotes M2 TAM recruitment and augments xenograft growth. Furthermore,
POSTN is also able to inhibit macrophage maturation. In addition, intracranial co-transplantation of M2 TAMs with GSCs significantly promotes tumor growth and shortens the survival of mice compared with the transplantation of GSCs alone. Mice co-transplanted with M2 TAMs and POSTN-silenced GSCs show a shortened survival relative to mice implanted with POSTN-silenced GSCs alone. Thus, M2 TAMs are recruited by GSC-derived POSTN and play a critical role in mediating POSTN-promoted GBM growth.

Although these findings provide new insights into how TAMs are recruited to promote GBM tumor growth, several questions remain unanswered. POSTN is a multifunctional matricellular protein that has an important role in regulating the inflammatory and tumor microenvironments (Conway et al., 2014; Liu et al., 2014; Wu and Ouyang, 2014). Apart from recruiting TAMs to promote GBM tumor growth, whether POSTN has a direct impact on remodeling the tumor microenvironment in GBMs, and especially the GSC perivascular niche, is unclear. As a Th2 cytokine, POSTN can be induced by TGF-β, IL-4, IL-13, IL-17, TNF-α, histamine, glucose and palmitate and can directly bind type 1 collagen, fibronectin, tenascin-C, BMP-1, Notch1 and itself, in addition to being regulated by Twist1, Twist2, STAT3, c-Jun, ChREBP and YY1 in the context of tissue injury, inflammation, fibrosis and/or tumors (Masuoka et al., 2012; Liu et al., 2014; Lu et al., 2014; Wu et al., 2014). Thus, the microenvironmental cues, transcription factors and microRNAs that directly induce or regulate POSTN expression in GSCs remain to be identified. GSCs have the ability to transdifferentiate into pericytes and endothelial cells in GBMs (Ricci-Vitiani et al., 2010; Wang et al., 2010; Cheng et al., 2013; Liu and Ouyang, 2013), but whether these GSC-derived pericytes and endothelial cells still secrete POSTN and have the potential to recruit TAMs, similar to GSCs, is unknown. It is also unclear whether GSCs can directly transdifferentiate into TAMs, at least in part. Interestingly, our recent work demonstrates that the activated hepatic stellate cells-derived POSTN might act as a chemoattractant factor to recruit macrophages into mouse acute and chronic fibrotic liver tissues (Huang et al., 2015). GSCs can secrete POSTN to recruit TAMs in GBMs, and POSTN knockdown significantly decreases TAMs in GSC-derived xenografts, but whether POSTN can act as a chemoattractant to recruit TAMs or other cells in other tumors remains to be determined. POSTN significantly promotes colon cancer cells metastasis to the liver by promoting the survival of cancer cells and endothelial cells (Bao et al., 2004). In breast cancer, fibroblast-derived POSTN is crucial for breast cancer stem cell expansion during metastatic colonization in lung (Malanchi et al., 2012; Wang and Ouyang, 2012), which is very different from the function of GSC-derived POSTN in GBMs. This difference and the effects of GSC-derived POSTN on non-stem cancer cells in tumor bulk still need to be investigated.

The finding of Zhou et al. (2015) that targeting POSTN significantly inhibits GBM tumor growth, mainly by reducing TAM recruitment and inducing massive apoptosis in GSC-derived xenografts, indicates that targeting POSTN-mediated TAM recruitment may improve GBM treatment. Interestingly, continuous anti-macrophage therapy with CCL2 neutralization by blocking the binding of CCL2 to CCR2-...
expressing monocytes impairs monocyte infiltration into primary mammary tumors and lung metastases in mice (Qian et al., 2011). However, a recent report demonstrated that cessation of anti-CCL2 therapy unexpectedly results in accelerated lung metastasis in mice (Bonapace et al., 2014). Considering that silencing POSTN expression has no marked direct impact on the GSC population, cancer cell proliferation or vascular density in tumor bulk, we do not know whether TAM recruitment will rapidly rebound in tumors and lead to lethal relapse after withdrawal of POSTN-targeting therapy. Therefore, targeting POSTN-mediated TAM recruitment may be more effective in fighting GBMs when used in synergy with other therapies.

**NOTES**

This work was supported by funds from the National Natural Science Foundation of China (Grant Nos. 81372841, 31171339 and 31071302), the Fundamental Research Funds for the Central Universities, the Program for New Century Excellent Talents in University (NCET-11-0296), and the FJNSF (2010J06013) to G.O.

Tiantian Wu, Qi Luo and Gaoliang Ouyang declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by the any of the authors.

**OPEN ACCESS**

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**REFERENCES**

Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF (2004) Periostin potently promotes metastastic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5:329–339

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radiosensitivity by preferential activation of the DNA damage response. Nature 444:756–760

Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Jun T, Bentires-Alj M (2014) Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515:130–133

Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, Min W, McLendon RE, Rich JN, Bao S (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139–152

Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CT, Kudo A (2014) The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 71:1279–1288

Gilbertson RJ, Rich JN (2007) Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7:733–736

Huang YM, Liu W, Xiao H, Maltikabili A, Lin Q, Wu T, Huang Z, Liu F, Luo Q, Ouyang G (2015) Matricular protein periostin contributes to hepatic inflammation and fibrosis. Am J Pathol 185:786–797

Liu AY, Ouyang G (2013) Tumor angiogenesis: a new source of pericytes. Curr Biol 23:R565–R568

Liu AY, Zheng H, Ouyang G (2014) Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol 37:150–156

Lu Y, Liu X, Jiao Y, Xiong X, Wang E, Wang X, Zhang Z, Zhang H, Pan L, Guan Y, Cai D, Ning G, Li X (2014) Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest 124:3501–3513

Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelskens J (2012) Interactions between cancer stem cell and their niche govern metastatic colonization. Nature 481:85–89

Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, Toda S, Inagaki N, Kurihara Y, Hayashida S, Takeuchi S, Koike K, Ono J, Noshiro H, Furue M, Conway SJ, Narisawa Y, Izuhara K (2012) Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 122:2590–2600

Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:222–225

Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824–828

Wang Z, Ouyang G (2012) Periostin: a bridge between cancer stem cells and their metastatic niche. Cell Stem Cell 20:111–112

Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Filgelman B, Leversha M, Brennan C, Tabar V (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468:829–833

Wu T, Ouyang G (2014) Matricular proteins: multifaceted extracellular regulators in tumor dormancy. Protein Cell 5:249–252

Wu T, Wu S, Ouyang G (2014) Periostin: a new extracellular regulator of obesity-induced hepatosteatosis. Cell Metab 20:562–564

Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich JN, Bao S (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumor-associated macrophages and promotes malignant growth. Nat Cell Biol 17:170–182